Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.88 |
| ▸ | PGR | P06401 | 6/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.78 |
| ▸ | USP2 | O75604 | 5/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | MLNR | O43193 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.78 |
| ▸ | PPARG | P37231 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28099304 | 1.00 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL11124627 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL29410388 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL11750078 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL36599 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL29572705 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL14339619 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| Clobetasone Butyrate SCHEMBL448850 | 0.94 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| SCHEMBL732359 | 0.93 | LMNA (0.92) | LMNAMAPTSMN1; SMN2NPSR1PGR | |
| SCHEMBL4100798 | 0.92 | LMNA (0.82) | LMNAMAPTSMN1; SMN2NPSR1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108778316-B | Treatment of respiratory diseases with glucocorticoid in combination with polyethylene glycol modified interleukin 2 | 谢彦晖 | 2023-07-04 | — | — | CN | claimed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | claimed |
| EP-4153299-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Rodeo Therapeutics Corporation (US) | 2023-03-29 | — | — | EP | claimed |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION | 2023-02-09 | — | — | US | claimed |
| CN-115109850-A | Use of AKT2 in diagnosis and treatment of tumors | 谢彦晖 | 2022-09-27 | — | — | CN | claimed |
| WO-2021236779-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION (US) | 2021-11-25 | — | — | WO | claimed |
| EP-3883577-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-09-29 | — | — | EP | claimed |
| CN-111132982-A | Compositions and methods for modulating short-chain dehydrogenase activity | 卡斯西部储备大学 | 2020-05-08 | — | — | CN | claimed |
| EP-3630773-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Case Western Reserve University (US) | 2020-04-08 | — | — | EP | claimed |
| US-20200061073-A1 | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-20070281914-A1 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | US | claimed |
| US-20070280995-A1 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | US | claimed |
| EP-1773350-A2 | OPTHALMIC COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | Allergan, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7201914-B2 | Combination antiperspirant and antimicrobial composition | XANTECH PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| US-20060115503-A1 | Composition, system and method for treatment of skin | GOYAL MUNA C | 2006-06-01 | — | — | US | claimed |
| WO-2006017347-A2 | OPTHALMIC COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | ALLERGAN, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060009498-A1 | Ophthalmic compositions and methods for treating ophthalmic conditions | ALLERGAN, INC. (US) | 2006-01-12 | — | — | US | claimed |
| US-20030215408-A1 | Combination antiperspirant and antimicrobial composition | XANTECH PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | claimed |
| EP-1362581-A2 | Combination antiperspirant and antimicrobial compositions | Xantech Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | claimed |
| US-6383495-B1 | CORNS, ECZEMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061073-A1 | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF | HPGD, HPGDS, PTGIS | LMNA 3938/4885MAPT 3648/4885SMN1; SMN2 4819/4885 |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | LMNA 1481/4885MAPT 4066/4885SMN1; SMN2 2443/4885 |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | LMNA 1481/4885MAPT 4066/4885SMN1; SMN2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.